Showing 281-290 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494.000,00 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2026 | $750.000,00 |
| Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults with Type 1 Diabetes | Albert Einstein College of Medicine | Jeffrey Gonzalez | Improving Lives | 01-December-2022 to 30-November-2026 | $1.672.180,00 |
| Inflammatory cytokines rewire the proinsulin interaction network in human islets | Sanford-Burnham Medical Research Institute | Pamela Itkin-Ansari | Cures | 01-May-2022 to 30-April-2025 | $987.642,98 |
| Synthetic Hydrogels for Islet Vascularization and Engraftment | Georgia Tech Research Corporation | Andres Garcia | Cures | 01-July-2022 to 30-June-2026 | $563.235,05 |
| Investigation of novel local immunomodulating strategies to enhance islet transplantation for T1D | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-July-2022 to 30-June-2026 | $962.995,99 |
| Changing the T1DE: A randomized controlled trial comparing ACT to supportive diabetes counseling | Duke University | Rhonda Merwin | Improving Lives | 01-July-2022 to 30-June-2027 | $2.534.224,22 |
| In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-August-2022 to 31-July-2025 | $699.997,82 |
| Innovating Methods for AssessinG INsulin Action in Type ONe diabetes (IMAGINATiON) | Regents of the University of Colorado | Kristen Nadeau | Improving Lives | 01-December-2021 to 30-November-2025 | $445.816,29 |
| EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM | Regents of the University of Colorado | Janet Snell-Bergeon | Improving Lives | 01-November-2022 to 31-October-2025 | $2.282.771,83 |